Otis
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|----------------------|----------------|--------------|------------|--------------------|--------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.65 | 1 | NC* | Male | 0.44 | 0 | NC* |
| Female | 0.25 | 0 | NC* | Female | 0.33 | 0 | NC* |
| Total | 0.90 | 1 | NC* | Total | 0.77 | 0 | NC* |
| Brain and Other Cen | tral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 0.24 | 1 | NC* | Male | 0.13 | 0 | NC* |
| Female | 0.18 | 1 | NC* | Female | 0.11 | 0 | NC* |
| Total | 0.42 | 2 | NC* | Total | 0.24 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyr | mphoma | | |
| Male | 0.04 | 0 | NC* | Male | 0.56 | 0 | NC* |
| Female | 4.09 | 2 | NC* | Female | 0.47 | 0 | NC* |
| Total | 4.13 | 2 | NC* | Total | 1.02 | 0 | NC* |
| Cervix Uteri | | | | Oral Cavity and Ph | <u>arynx</u> | | |
| | | | | Male | 0.46 | 0 | NC* |
| Female | 0.26 | 1 | NC* | Female | 0.20 | 0 | NC* |
| | | | | Total | 0.66 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.66 | 2 | NC* | - | | | |
| Female | 1.55 | 1 | NC* | Female | 0.49 | 1 | NC* |
| Total | 3.21 | 3 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.25 | 0 | NC* | Male | 0.27 | 0 | NC* |
| Female | 0.08 | 0 | NC* | Female | 0.27 | 0 | NC* |
| Total | 0.33 | 0 | NC* | Total | 0.53 | 0 | NC* |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 0.12 | 0 | NC* | Male | 4.14 | 4 | NC* |
| Female | 0.09 | 0 | NC* | | | | |
| Total | 0.21 | 0 | NC* | | | | |
| Kidney and Renal Pe | | | | <u>Stomach</u> | | | |
| Male | 0.41 | 0 | NC* | Male | 0.28 | 0 | NC* |
| Female | 0.24 | 0 | NC* | Female | 0.17 | 0 | NC* |
| Total | 0.64 | 0 | NC* | Total | 0.45 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.24 | 0 | NC* | | 0.19 | 0 | NC* |
| Female | 0.06 | 0 | NC* | | | | |
| Total | 0.29 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.30 | 0 | NC* | Male | 0.10 | 0 | NC* |
| Female | 0.23 | 1 | NC* | Female | 0.24 | 0 | NC* |
| Total | 0.53 | 1 | NC* | Total | 0.34 | 0 | NC* |
| Liver and Intrahepat | | | | Uteri, Corpus and | | | |
| Male | 0.15 | 0 | NC* | | <u> </u> | | |
| Female | 0.06 | 0 | NC* | Female | 0.77 | 1 | NC* |
| Total | 0.21 | 0 | NC* | | | | |
| Lung and Bronchus | | - | | All Sites / Types | | | |
| Male | 2.18 | 1 | NC* | Male | 13.72 | 9 | 66 |
| Female | 1.61 | 2 | NC* | Female | 12.65 | 11 | 87 |
| Total | 3.79 | 3 | NC* | Total | 26.37 | 20 | 76 |
| · Juli | J, | J | | 1000 | _0.0, | | . 0 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the p<0.05 level
- \sim indicates statistical significance at the **p** \leq 0.01 level, as well as at the **p** \leq 0.05 level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Oxford
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------|-----------------|--------------|------------|--------------------|---------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 7.21 | 7 | 97 | Male | 4.74 | 6 | 127 |
| Female | 2.78 | 3 | NC* | Female | 3.77 | 2 | NC* |
| Total | 9.99 | 10 | 100 | Total | 8.51 | 8 | 94 |
| Brain and Other Ce | ntral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 2.55 | 4 | NC* | Male | 1.37 | 3 | NC* |
| Female | 2.03 | 3 | NC* | Female | 1.25 | 2 | NC* |
| Total | 4.57 | 7 | 153 | Total | 2.62 | 5 | 191 |
| <u>Breast</u> | | | | Non-Hodgkin's Ly | mphoma | | |
| Male | 0.47 | 1 | NC* | Male | 6.02 | 6 | 100 |
| Female | 46.87 | 43 | 92 | Female | 5.31 | 7 | 132 |
| Total | 47.33 | 44 | 93 | Total | 11.33 | 13 | 115 |
| Cervix Uteri | | | | Oral Cavity and Ph | <u>iarynx</u> | | |
| | | | | Male | 4.87 | 4 | NC* |
| Female | 3.00 | 4 | NC* | Female | 2.27 | 1 | NC* |
| | | | | Total | 7.14 | 5 | 70 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 18.18 | 13 | 72 | | | | |
| Female | 17.38 | 18 | 104 | Female | 5.57 | 7 | 126 |
| Total | 35.56 | 31 | 87 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 2.68 | 2 | NC* | Male | 2.89 | 6 | 207 |
| Female | 0.89 | 1 | NC* | Female | 3.03 | 3 | NC* |
| Total | 3.57 | 3 | NC* | Total | 5.92 | 9 | 152 |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 1.29 | 1 | NC* | Male | 44.07 | 44 | 100 |
| Female | 1.05 | 1 | NC* | | | | |
| Total | 2.34 | 2 | NC* | | | | |
| Kidney and Renal I | | | | <u>Stomach</u> | | | |
| Male | 4.33 | 9 | 208 | Male | 3.08 | 2 | NC* |
| Female | 2.71 | 5 | 185 | Female | 1.88 | 2 | NC* |
| Total | 7.04 | 14 | 199 #+ | Total | 4.95 | 4 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 2.49 | 1 | NC* | Male | 1.99 | 4 | NC* |
| Female | 0.68 | 0 | NC* | | | | |
| Total | 3.17 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |

| Male | 3.31 | 4 | NC* | Male | 1.01 | 2 | NC* | |
|--|-----------|----|-----|-------------------------------|--------|-----|-----|--|
| Female | 2.62 | 3 | NC* | Female | 2.75 | 1 | NC* | |
| Total | 5.93 | 7 | 118 | Total | 3.76 | 3 | NC* | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 1.60 | 0 | NC* | | | | | |
| Female | 0.65 | 0 | NC* | Female | 8.92 | 4 | NC* | |
| Total | 2.25 | 0 | NC* | | | | | |
| Lung and Bronch | <u>us</u> | | | All Sites / Types | | | | |
| Male | 23.32 | 20 | 86 | Male | 147.67 | 149 | 101 | |
| Female | 18.54 | 15 | 81 | Female | 144.25 | 138 | 96 | |
| Total | 41.86 | 35 | 84 | Total | 291.92 | 287 | 98 | |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

PalmerExpected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| Bladder, Urinary Melanoma of Skin | |
|--|-----|
| Male 8.54 12 141 Male 5.10 4 | NC* |
| Female 3.45 6 174 Female 3.99 5 | 125 |
| Total 11.99 18 150 Total 9.09 9 | 99 |
| Brain and Other Central Nervous System <u>Multiple Myeloma</u> | |
| Male 2.63 2 NC* Male 1.59 0 | NC* |
| Female 2.14 4 NC* Female 1.48 3 | NC* |
| Total 4.77 6 126 Total 3.07 3 | NC* |
| Breast Non-Hodgkin's Lymphoma | |
| Male 0.53 0 NC* Male 6.52 5 | 77 |
| Female 51.09 51 100 Female 6.15 2 | NC* |
| Total 51.63 51 99 Total 12.67 7 | 55 |
| <u>Cervix Uteri</u> <u>Oral Cavity and Pharynx</u> | |
| Male 5.16 3 | NC* |
| Female 2.97 7 235 Female 2.57 0 | NC* |
| Total 7.73 3 | NC* |
| <u>Colon / Rectum</u> <u>Ovary</u> | |
| Male 21.38 24 112 | |
| Female 21.73 14 64 Female 5.97 11 | 184 |
| Total 43.11 38 88 | |
| <u>Esophagus</u> <u>Pancreas</u> | |
| Male 2.98 2 NC* Male 3.29 5 | 152 |
| Female 1.12 1 NC* Female 3.75 2 | NC* |
| Total 4.10 3 NC* Total 7.04 7 | 99 |
| <u>Hodgkin's Disease</u> <u>Prostate</u> | |
| Male 1.22 0 NC* Male 50.39 45 | 89 |

[^] indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

| Female | 1.01 | 1 | NC* | | | | |
|----------------------|----------------|----|--------|-------------------------------|--------|-----|-----|
| Total | 2.24 | 1 | NC* | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | Stomach | | | |
| Male | 4.77 | 8 | 168 | Male | 3.56 | 4 | NC* |
| Female | 3.08 | 2 | NC* | Female | 2.34 | 5 | 213 |
| Total | 7.84 | 10 | 127 | Total | 5.90 | 9 | 152 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 2.71 | 10 | 369 ~+ | Male | 1.83 | 1 | NC* |
| Female | 0.74 | 2 | NC* | | | | |
| Total | 3.45 | 12 | 348 ^+ | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 3.61 | 4 | NC* | Male | 0.99 | 0 | NC* |
| Female | 2.92 | 4 | NC* | Female | 2.65 | 3 | NC* |
| Total | 6.53 | 8 | 123 | Total | 3.64 | 3 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 1.75 | 6 | 342 #+ | | | | |
| Female | 0.79 | 1 | NC* | Female | 9.79 | 9 | 92 |
| Total | 2.54 | 7 | 276 #+ | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 26.80 | 33 | 123 | Male | 166.80 | 182 | 109 |
| Female | 21.35 | 26 | 122 | Female | 163.39 | 165 | 101 |
| Total | 48.15 | 59 | 123 | Total | 330.20 | 347 | 105 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

PaxtonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|---------------------|----------------|--------------|------------|---------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 3.20 | 3 | NC* | Male | 1.97 | 4 | NC* |
| Female | 1.09 | 0 | NC* | Female | 1.43 | 2 | NC* |
| Total | 4.28 | 3 | NC* | Total | 3.40 | 6 | 177 |
| Brain and Other Cen | tral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 1.01 | 0 | NC* | Male | 0.61 | 0 | NC* |
| Female | 0.77 | 2 | NC* | Female | 0.51 | 1 | NC* |
| Total | 1.78 | 2 | NC* | Total | 1.12 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyn | <u>nphoma</u> | | |
| Male | 0.21 | 1 | NC* | Male | 2.46 | 3 | NC* |
| Female | 18.89 | 18 | 95 | Female | 2.07 | 1 | NC* |
| Total | 19.10 | 19 | 99 | Total | 4.53 | 4 | NC* |
| Cervix Uteri | | | | Oral Cavity and Pha | <u>arynx</u> | | |
| | | | | Male | 2.10 | 0 | NC* |
| Female | 1.10 | 2 | NC* | Female | 0.91 | 0 | NC* |

| | | | | Total | 3.01 | 0 | NC* | |
|------------------------|------------------|---|-------|-------------------------------|--------|----|-------|--|
| Colon / Rectum | | | | <u>Ovary</u> | | | | |
| Male | 8.06 | 2 | NC* | | | | | |
| Female | 6.78 | 5 | 74 | Female | 2.21 | 1 | NC* | |
| Total | 14.84 | 7 | 47 #- | | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | | |
| Male | 1.20 | 0 | NC* | Male | 1.28 | 2 | NC* | |
| Female | 0.35 | 0 | NC* | Female | 1.20 | 0 | NC* | |
| Total | 1.54 | 0 | NC* | Total | 2.48 | 2 | NC* | |
| Hodgkin's Diseas | <u>se</u> | | | <u>Prostate</u> | | | | |
| Male | 0.42 | 0 | NC* | Male | 20.07 | 16 | 80 | |
| Female | 0.35 | 0 | NC* | | | | | |
| Total | 0.77 | 0 | NC* | | | | | |
| Kidney and Rena | <u>l Pelvis</u> | | | Stomach | | | | |
| Male | 1.89 | 4 | NC* | Male | 1.34 | 1 | NC* | |
| Female | 1.10 | 1 | NC* | Female | 0.72 | 1 | NC* | |
| Total | 2.98 | 5 | 168 | Total | 2.06 | 2 | NC* | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 1.11 | 1 | NC* | Male | 0.58 | 1 | NC* | |
| Female | 0.29 | 0 | NC* | | | | | |
| Total | 1.40 | 1 | NC* | | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | | |
| Male | 1.35 | 0 | NC* | Male | 0.38 | 1 | NC* | |
| Female | 0.99 | 0 | NC* | Female | 0.97 | 2 | NC* | |
| Total | 2.34 | 0 | NC* | Total | 1.34 | 3 | NC* | |
| Liver and Intrahe | patic Bile Ducts | | | Uteri, Corpus and Uterus, NOS | | | | |
| Male | 0.70 | 0 | NC* | | | | | |
| Female | 0.26 | 0 | NC* | Female | 3.69 | 6 | 163 | |
| Total | 0.95 | 0 | NC* | | | | | |
| Lung and Bronch | <u>ius</u> | | | All Sites / Types | | | | |
| Male | 10.47 | 3 | NC* | Male | 64.63 | 45 | 70 #- | |
| Female | 7.66 | 5 | 65 | Female | 57.29 | 52 | 91 | |
| Total | 18.13 | 8 | 44 #- | Total | 121.92 | 97 | 80 #- | |

Obs = observed case count

SIR = standardized incidence ratio [Obs / Exp) X 100]

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

PeabodyExpected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|------------------|------------|------------|------------|------------------|------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 34.24 | 41 | 120 | Male | 21.19 | 24 | 113 |
| Female | 13.51 | 15 | 111 | Female | 16.48 | 11 | 67 |
| Total | 47.75 | 56 | 117 | Total | 37.67 | 35 | 93 |

[^] indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

| Brain and Other Co | entral Nervous S | <u>ystem</u> | | Multiple Myeloma | <u>!</u> | | |
|--------------------|------------------|--------------|--------|-------------------|---------------|------|--------|
| Male | 10.95 | 11 | 100 | Male | 6.44 | 9 | 140 |
| Female | 8.79 | 3 | NC* | Female | 6.00 | 7 | 117 |
| Total | 19.74 | 14 | 71 | Total | 12.44 | 16 | 129 |
| <u>Breast</u> | | | | Non-Hodgkin's L | ymphoma | | |
| Male | 2.19 | 2 | NC* | Male | 26.76 | 34 | 127 |
| Female | 214.19 | 236 | 110 | Female | 24.71 | 29 | 117 |
| Total | 216.37 | 238 | 110 | Total | 51.47 | 63 | 122 |
| Cervix Uteri | | | | Oral Cavity and P | <u>harynx</u> | | |
| | | | | Male | 22.03 | 24 | 109 |
| Female | 12.52 | 12 | 96 | Female | 10.57 | 11 | 104 |
| | | | | Total | 32.60 | 35 | 107 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 86.53 | 96 | 111 | | | | |
| Female | 84.49 | 84 | 99 | Female | 25.05 | 22 | 88 |
| Total | 171.02 | 180 | 105 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 12.58 | 14 | 111 | Male | 13.61 | 19 | 140 |
| Female | 4.36 | 1 | NC* | Female | 14.79 | 16 | 108 |
| Total | 16.94 | 15 | 89 | Total | 28.40 | 35 | 123 |
| Hodgkin's Disease | 1 | | | <u>Prostate</u> | | | |
| Male | 5.01 | 8 | 160 | Male | 212.52 | 226 | 106 |
| Female | 4.09 | 3 | NC* | | | | |
| Total | 9.10 | 11 | 121 | | | | |
| Kidney and Renal I | <u>Pelvis</u> | | | <u>Stomach</u> | | | |
| Male | 19.91 | 34 | 171 ~+ | Male | 14.38 | 6 | 42 #- |
| Female | 12.69 | 15 | 118 | Female | 9.05 | 10 | 111 |
| Total | 32.59 | 49 | 150 ~+ | Total | 23.43 | 16 | 68 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 11.59 | 18 | 155 | Male | 7.47 | 5 | 67 |
| Female | 3.19 | 3 | NC* | | | | |
| Total | 14.78 | 21 | 142 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 14.53 | 17 | 117 | Male | 4.20 | 1 | NC* |
| Female | 11.57 | 12 | 104 | Female | 11.07 | 12 | 108 |
| Total | 26.11 | 29 | 111 | Total | 15.27 | 13 | 85 |
| Liver and Intrahep | atic Bile Ducts | | | Uteri, Corpus and | d Uterus, NOS | | |
| Male | 7.37 | 10 | 136 | • | | | |
| Female | 3.12 | 0 | NC* | Female | 41.41 | 54 | 130 |
| Total | 10.49 | 10 | 95 | | | | |
| Lung and Bronchu | | | | All Sites / Types | | | |
| Male | 111.30 | 138 | 124 #+ | Male | 690.90 | 785 | 114 ^+ |
| Female | 88.66 | 97 | 109 | Female | 668.58 | 710 | 106 |
| Total | 199.95 | 235 | 118 #+ | Total | 1359.48 | 1495 | 110 ^+ |

Obs = observed case count

 $^{^{\}star}$ = S1R and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $p \le 0.05$ level

- \sim indicates statistical significance at the $p{\le}0.01$ level, as well as at the $p{\le}0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Pelham
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------------|----------------------|--------------|------------|---------------------|--------------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 1.05 | 0 | NC* | Male | 0.64 | 1 | NC* |
| Female | 0.29 | 0 | NC* | Female | 0.44 | 0 | NC* |
| Total | 1.34 | 0 | NC* | Total | 1.08 | 1 | NC* |
| Brain and Other Centr | <u>ral Nervous S</u> | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 0.33 | 0 | NC* | Male | 0.19 | 0 | NC* |
| Female | 0.23 | 0 | NC* | Female | 0.14 | 0 | NC* |
| Total | 0.56 | 0 | NC* | Total | 0.34 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyn | <u>nphoma</u> | | |
| Male | 0.07 | 0 | NC* | Male | 0.81 | 0 | NC* |
| Female | 5.56 | 6 | 108 | Female | 0.59 | 0 | NC* |
| Total | 5.63 | 6 | 107 | Total | 1.40 | 0 | NC* |
| Cervix Uteri | | | | Oral Cavity and Pha | <u>arynx</u> | | |
| | | | | Male | 0.68 | 0 | NC* |
| Female | 0.36 | 0 | NC* | Female | 0.26 | 0 | NC* |
| | | | | Total | 0.94 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 2.65 | 2 | NC* | | | | |
| Female | 1.80 | 2 | NC* | Female | 0.66 | 0 | NC* |
| Total | 4.45 | 4 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.39 | 0 | NC* | Male | 0.42 | 1 | NC* |
| Female | 0.09 | 0 | NC* | Female | 0.32 | 0 | NC* |
| Total | 0.48 | 0 | NC* | Total | 0.74 | 1 | NC* |
| Hodgkin's Disease | | | | Prostate | | | |
| Male | 0.15 | 0 | NC* | Male | 6.55 | 5 | 76 |
| Female | 0.12 | 0 | NC* | | | | |
| Total | 0.26 | 0 | NC* | | | | |
| Kidney and Renal Pelv | <u>vis</u> | | | Stomach | | | |
| Male | 0.60 | 3 | NC* | Male | 0.44 | 0 | NC* |
| Female | 0.31 | 0 | NC* | Female | 0.19 | 0 | NC* |
| Total | 0.91 | 3 | NC* | Total | 0.64 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.36 | 0 | NC* | Male | 0.21 | 0 | NC* |
| Female | 0.08 | 0 | NC* | | | | |
| Total | 0.44 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.44 | 0 | NC* | Male | 0.13 | 1 | NC* |
| Female | 0.28 | 0 | NC* | Female | 0.33 | 0 | NC* |
| Total | 0.72 | 0 | NC* | Total | 0.45 | 1 | NC* |
| Liver and Intrahepation | Bile Ducts | | | Uteri, Corpus and L | <u>Jterus, NOS</u> | | |
| Male | 0.23 | 0 | NC* | | | | |
| Female | 0.07 | 0 | NC* | Female | 1.07 | 2 | NC* |
| Total | 0.30 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |

| Male | 3.40 | 2 | NC* | Male | 21.15 | 18 | 85 |
|--------|------|---|-----|--------|-------|----|----|
| Female | 2.16 | 0 | NC* | Female | 16.42 | 11 | 67 |
| Total | 5.55 | 2 | NC* | Total | 37.57 | 29 | 77 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Pembroke
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> | | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> |
|----------------------------|-----------------|--------------|------------|--------------------|---------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 7.52 | 21 | 279 ^+ | Male | 5.47 | 6 | 110 |
| Female | 2.68 | 4 | NC* | Female | 4.14 | 4 | NC* |
| Total | 10.19 | 25 | 245 ^+ | Total | 9.61 | 10 | 104 |
| Brain and Other Cer | ntral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 2.99 | 1 | NC* | Male | 1.49 | 1 | NC* |
| Female | 2.21 | 4 | NC* | Female | 1.28 | 3 | NC* |
| Total | 5.20 | 5 | 96 | Total | 2.77 | 4 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Ly | mphoma | | |
| Male | 0.51 | 0 | NC* | Male | 6.79 | 8 | 118 |
| Female | 51.51 | 60 | 116 | Female | 5.40 | 5 | 93 |
| Total | 52.02 | 60 | 115 | Total | 12.19 | 13 | 107 |
| Cervix Uteri | | | | Oral Cavity and Ph | <u>narynx</u> | | |
| | | | | Male | 5.84 | 5 | 86 |
| Female | 3.41 | 6 | 176 | Female | 2.41 | 1 | NC* |
| | | | | Total | 8.25 | 6 | 73 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 19.07 | 22 | 115 | | | | |
| Female | 16.66 | 19 | 114 | Female | 6.16 | 11 | 179 |
| Total | 35.73 | 41 | 115 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 3.06 | 5 | 163 | Male | 3.17 | 4 | NC* |
| Female | 0.84 | 3 | NC* | Female | 2.91 | 2 | NC* |
| Total | 3.90 | 8 | 205 | Total | 6.08 | 6 | 99 |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 1.51 | 4 | NC* | Male | 48.46 | 60 | 124 |
| Female | 1.15 | 0 | NC* | | | | |
| Total | 2.67 | 4 | NC* | | | | |
| Kidney and Renal P | <u>elvis</u> | | | Stomach | | | |
| Male | 5.00 | 6 | 120 | Male | 3.28 | 4 | NC* |
| Female | 2.82 | 1 | NC* | Female | 1.80 | 1 | NC* |
| Total | 7.82 | 7 | 89 | Total | 5.09 | 5 | 98 |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 2.93 | 1 | NC* | Male | 2.31 | 3 | NC* |

| Female | 0.74 | 0 | NC* | | | | |
|---------------------|----------------|----|--------|-------------------|-------------|-----|--------|
| Total | 3.67 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 3.70 | 3 | NC* | Male | 1.23 | 0 | NC* |
| Female | 2.78 | 2 | NC* | Female | 3.13 | 5 | 160 |
| Total | 6.48 | 5 | 77 | Total | 4.36 | 5 | 115 |
| Liver and Intrahepa | tic Bile Ducts | | | Uteri, Corpus and | Uterus, NOS | | |
| Male | 1.83 | 0 | NC* | | | | |
| Female | 0.64 | 1 | NC* | Female | 9.80 | 15 | 153 |
| Total | 2.47 | 1 | NC* | | | | |
| Lung and Bronchus | <u>s</u> | | | All Sites / Types | | | |
| Male | 25.51 | 33 | 129 | Male | 162.75 | 198 | 122 ~+ |
| Female | 19.04 | 26 | 137 | Female | 151.94 | 184 | 121 #+ |
| Total | 44.55 | 59 | 132 #+ | Total | 314.69 | 382 | 121 ^+ |

Obs = observed case count

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- \sim indicates statistical significance at the p<0.01 level, as well as at the p<0.05 level

Pepperell
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|----------------------------|-----------------|---------------|-------------|--------------------|--------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | _ | | |
| Male | 4.36 | 10 | 229 #+ | Male | 3.39 | 5 | 147 |
| Female | 1.71 | 3 | NC* | Female | 2.72 | 1 | NC* |
| Total | 6.07 | 13 | 214 #+ | Total | 6.11 | 6 | 98 |
| Brain and Other Cer | ntral Nervous S | <u>System</u> | | Multiple Myeloma | | | |
| Male | 1.92 | 2 | NC* | Male | 0.88 | 1 | NC* |
| Female | 1.44 | 2 | NC* | Female | 0.81 | 1 | NC* |
| Total | 3.36 | 4 | NC* | Total | 1.69 | 2 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyr | mphoma | | |
| Male | 0.30 | 1 | NC* | Male | 4.22 | 1 | NC* |
| Female | 32.89 | 32 | 97 | Female | 3.47 | 5 | 144 |
| Total | 33.19 | 33 | 99 | Total | 7.69 | 6 | 78 |
| Cervix Uteri | | | | Oral Cavity and Ph | | | |
| | | | | Male | 3.59 | 4 | NC* |
| Female | 2.27 | 6 | 264 | Female | 1.54 | 2 | NC* |
| | | | | Total | 5.13 | 6 | 117 |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 11.07 | 11 | 99 | | | | |
| Female | 10.65 | 7 | 66 | Female | 3.96 | 3 | NC* |
| Total | 21.72 | 18 | 83 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.82 | 1 | NC* | Male | 1.86 | 2 | NC* |
| Female | 0.54 | 1 | NC* | Female | 1.85 | 1 | NC* |

[^] indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

| Total | 2.35 | 2 | NC* | Total | 3.71 | 3 | NC* |
|-------------------|------------------|----|-------|-------------------|-------------|-----|-----|
| Hodgkin's Diseas | <u>e</u> | | | Prostate | | | |
| Male | 1.04 | 0 | NC* | Male | 28.10 | 23 | 82 |
| Female | 0.79 | 3 | NC* | | | | |
| Total | 1.83 | 3 | NC* | | | | |
| Kidney and Renal | <u>Pelvis</u> | | | Stomach | | | |
| Male | 3.05 | 5 | 164 | Male | 1.93 | 1 | NC* |
| Female | 1.78 | 3 | NC* | Female | 1.17 | 0 | NC* |
| Total | 4.83 | 8 | 166 | Total | 3.10 | 1 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.76 | 2 | NC* | Male | 1.63 | 1 | NC* |
| Female | 0.46 | 1 | NC* | | | | |
| Total | 2.22 | 3 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 2.33 | 2 | NC* | Male | 0.81 | 0 | NC* |
| Female | 1.82 | 2 | NC* | Female | 2.11 | 4 | NC* |
| Total | 4.15 | 4 | NC* | Total | 2.92 | 4 | NC* |
| Liver and Intrahe | patic Bile Ducts | | | Uteri, Corpus and | Uterus, NOS | | |
| Male | 1.10 | 1 | NC* | | | | |
| Female | 0.41 | 1 | NC* | Female | 6.18 | 3 | NC* |
| Total | 1.51 | 2 | NC* | | | | |
| Lung and Bronch | <u>ius</u> | | | All Sites / Types | | | |
| Male | 14.94 | 7 | 47 #- | Male | 96.90 | 86 | 89 |
| Female | 11.87 | 12 | 101 | Female | 97.19 | 97 | 100 |
| Total | 26.81 | 19 | 71 | Total | 194.09 | 183 | 94 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Peru Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|---------------------|----------------|--------------|------------|-------------------|------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.51 | 0 | NC* | Male | 0.32 | 0 | NC* |
| Female | 0.13 | 0 | NC* | Female | 0.20 | 1 | NC* |
| Total | 0.64 | 0 | NC* | Total | 0.52 | 1 | NC* |
| Brain and Other Cen | tral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 0.17 | 0 | NC* | Male | 0.10 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.06 | 0 | NC* |
| Total | 0.28 | 0 | NC* | Total | 0.16 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyr | mphoma | | |
| Male | 0.03 | 0 | NC* | Male | 0.40 | 0 | NC* |
| Female | 2.44 | 1 | NC* | Female | 0.27 | 0 | NC* |
| Total | 2.48 | 1 | NC* | Total | 0.67 | 0 | NC* |

| Cervix Uteri | | | | Oral Cavity and Pharynx | | | |
|------------------------|------------|---|-----|-------------------------|-------------|---|-------|
| | | | | Male | 0.33 | 0 | NC* |
| Female | 0.17 | 0 | NC* | Female | 0.12 | 0 | NC* |
| | | | | Total | 0.45 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.28 | 0 | NC* | | | | |
| Female | 0.81 | 0 | NC* | Female | 0.30 | 0 | NC* |
| Total | 2.09 | 0 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.18 | 0 | NC* | Male | 0.20 | 0 | NC* |
| Female | 0.04 | 0 | NC* | Female | 0.14 | 0 | NC* |
| Total | 0.23 | 0 | NC* | Total | 0.34 | 0 | NC* |
| Hodgkin's Disease | | | | Prostate | | | |
| Male | 0.08 | 0 | NC* | Male | 3.04 | 1 | NC* |
| Female | 0.06 | 0 | NC* | | | | |
| Total | 0.14 | 0 | NC* | | | | |
| Kidney and Renal Pelv | <u>'is</u> | | | Stomach | | | |
| Male | 0.30 | 0 | NC* | Male | 0.22 | 0 | NC* |
| Female | 0.14 | 0 | NC* | Female | 0.09 | 0 | NC* |
| Total | 0.44 | 0 | NC* | Total | 0.30 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.17 | 0 | NC* | Male | 0.11 | 0 | NC* |
| Female | 0.04 | 0 | NC* | | | | |
| Total | 0.21 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.23 | 0 | NC* | Male | 0.06 | 0 | NC* |
| Female | 0.14 | 1 | NC* | Female | 0.16 | 1 | NC* |
| Total | 0.37 | 1 | NC* | Total | 0.22 | 1 | NC* |
| Liver and Intrahepatic | Bile Ducts | | | Uteri, Corpus and | Uterus, NOS | | |
| Male | 0.11 | 0 | NC* | • | | | |
| Female | 0.03 | 0 | NC* | Female | 0.46 | 0 | NC* |
| Total | 0.14 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 1.62 | 2 | NC* | Male | 10.16 | 3 | NC* |
| Female | 0.94 | 0 | NC* | Female | 7.34 | 6 | 82 |
| Total | 2.56 | 2 | NC* | Total | 17.50 | 9 | 51 #- |

Obs = observed case count

SIR = standardized incidence ratio [Obs / Exp) X 100]

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- \sim indicates statistical significance at the $p{\le}0.01$ level, as well as at the $p{\le}0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Petersham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Bladder, Urinary</u> <u>Melanoma of Skin</u>

| Male | 0.86 | 1 | NC* | Male | 0.53 | 0 | NC* |
|----------------------|------------------|-------|-----|--------------------|--------|----|-----|
| Female | 0.39 | 1 | NC* | Female | 0.41 | 0 | NC* |
| Total | 1.25 | 2 | NC* | Total | 0.94 | 0 | NC* |
| Brain and Other Cen | tral Nervous Sys | stem_ | | Multiple Myeloma | | | |
| Male | 0.27 | 0 | NC* | Male | 0.16 | 0 | NC* |
| Female | 0.22 | 0 | NC* | Female | 0.16 | 0 | NC* |
| Total | 0.49 | 0 | NC* | Total | 0.33 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Ly | mphoma | | |
| Male | 0.05 | 0 | NC* | Male | 0.66 | 1 | NC* |
| Female | 5.50 | 3 | NC* | Female | 0.66 | 0 | NC* |
| Total | 5.55 | 3 | NC* | Total | 1.33 | 1 | NC* |
| Cervix Uteri | | | | Oral Cavity and Ph | | | |
| | | | | Male | 0.56 | 0 | NC* |
| Female | 0.29 | 1 | NC* | Female | 0.28 | 0 | NC* |
| | | | | Total | 0.84 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 2.16 | 3 | NC* | | | | |
| Female | 2.44 | 0 | NC* | Female | 0.63 | 1 | NC* |
| Total | 4.60 | 3 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.32 | 0 | NC* | Male | 0.34 | 0 | NC* |
| Female | 0.13 | 0 | NC* | Female | 0.42 | 2 | NC* |
| Total | 0.44 | 0 | NC* | Total | 0.76 | 2 | NC* |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 0.12 | 0 | NC* | Male | 5.27 | 5 | 95 |
| Female | 0.09 | 0 | NC* | | | | |
| Total | 0.21 | 0 | NC* | | | | |
| Kidney and Renal Pe | | | | <u>Stomach</u> | | | |
| Male | 0.50 | 2 | NC* | Male | 0.36 | 0 | NC* |
| Female | 0.33 | 0 | NC* | Female | 0.26 | 0 | NC* |
| Total | 0.83 | 2 | NC* | Total | 0.63 | 0 | NC* |
| Larynx | | | | Testis | | | |
| Male | 0.29 | 0 | NC* | Male | 0.17 | 0 | NC* |
| Female | 0.08 | 0 | NC* | | | | |
| Total | 0.37 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.36 | 0 | NC* | Male | 0.10 | 0 | NC* |
| Female | 0.30 | 0 | NC* | Female | 0.25 | 0 | NC* |
| Total | 0.67 | 0 | NC* | Total | 0.35 | 0 | NC* |
| Liver and Intrahepat | | | | Uteri, Corpus and | | | |
| Male | 0.18 | 0 | NC* | <u> </u> | | | |
| Female | 0.09 | 0 | NC* | Female | 1.07 | 0 | NC* |
| Total | 0.27 | 0 | NC* | . Sindio | | - | |
| Lung and Bronchus | | ŭ | | All Sites / Types | | | |
| Male | 2.76 | 2 | NC* | Male | 17.17 | 14 | 82 |
| Female | 2.34 | 0 | NC* | Female | 17.69 | 11 | 62 |
| Total | 5.10 | 2 | NC* | Total | 34.86 | 25 | 72 |
| rotar | 0.10 | _ | 110 | iotai | 01.00 | 20 | 12 |

Obs = observed case count

^{*} = SIR and statistical significance not calculated when **Obs** < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the p≤0.05 level
- \sim indicates statistical significance at the $p{\le}0.01$ level, as well as at the $p{\le}0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Phillipston
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|----------------------|----------------|--------------|------------|-------------------------|--------------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.88 | 0 | NC* | Male | 0.64 | 0 | NC* |
| Female | 0.24 | 0 | NC* | Female | 0.42 | 0 | NC* |
| Total | 1.12 | 0 | NC* | Total | 1.06 | 0 | NC* |
| Brain and Other Cen | tral Nervous S | <u>ystem</u> | | <u>Multiple Myeloma</u> | | | |
| Male | 0.35 | 1 | NC* | Male | 0.17 | 0 | NC* |
| Female | 0.23 | 0 | NC* | Female | 0.12 | 1 | NC* |
| Total | 0.58 | 1 | NC* | Total | 0.29 | 1 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyr | <u>mphoma</u> | | |
| Male | 0.06 | 0 | NC* | Male | 0.80 | 1 | NC* |
| Female | 4.94 | 2 | NC* | Female | 0.52 | 0 | NC* |
| Total | 5.00 | 2 | NC* | Total | 1.32 | 1 | NC* |
| Cervix Uteri | | | | Oral Cavity and Pha | <u>arynx</u> | | |
| | | | | Male | 0.67 | 0 | NC* |
| Female | 0.36 | 0 | NC* | Female | 0.23 | 0 | NC* |
| | | | | Total | 0.90 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 2.23 | 1 | NC* | | | | |
| Female | 1.49 | 0 | NC* | Female | 0.60 | 0 | NC* |
| Total | 3.72 | 1 | NC* | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 0.35 | 0 | NC* | Male | 0.37 | 0 | NC* |
| Female | 0.07 | 0 | NC* | Female | 0.26 | 0 | NC* |
| Total | 0.43 | 0 | NC* | Total | 0.63 | 0 | NC* |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 0.18 | 0 | NC* | Male | 5.61 | 5 | 89 |
| Female | 0.13 | 1 | NC* | | | | |
| Total | 0.32 | 1 | NC* | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | Stomach | | | |
| Male | 0.58 | 0 | NC* | Male | 0.38 | 0 | NC* |
| Female | 0.27 | 0 | NC* | Female | 0.16 | 0 | NC* |
| Total | 0.85 | 0 | NC* | Total | 0.55 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.34 | 1 | NC* | Male | 0.29 | 1 | NC* |
| Female | 0.07 | 0 | NC* | | | | |
| Total | 0.41 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.43 | 0 | NC* | Male | 0.15 | 0 | NC* |
| Female | 0.27 | 1 | NC* | Female | 0.35 | 0 | NC* |
| Total | 0.70 | 1 | NC* | Total | 0.49 | 0 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and I | <u>Uterus, NOS</u> | | |
| Male | 0.21 | 0 | NC* | | | | |

| Female | 0.06 | 0 | NC* | Female | 0.92 | 0 | NC* |
|--------------------------|------|---|-----|-------------------|-------|----|-----|
| Total | 0.27 | 0 | NC* | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 2.96 | 1 | NC* | Male | 18.96 | 12 | 63 |
| Female | 1.80 | 4 | NC* | Female | 14.48 | 11 | 76 |
| Total | 4.76 | 5 | 105 | Total | 33.44 | 23 | 69 |

Obs = observed case count

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

PittsfieldExpected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> |
|--------------------|------------------------|--------------|------------|-------------------------|---------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 36.51 | 25 | 68 | Male | 20.93 | 14 | 67 |
| Female | 15.26 | 16 | 105 | Female | 16.60 | 9 | 54 |
| Total | 51.78 | 41 | 79 | Total | 37.54 | 23 | 61 #- |
| Brain and Other Ce | <u>ntral Nervous S</u> | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 10.56 | 10 | 95 | Male | 6.68 | 8 | 120 |
| Female | 8.93 | 6 | 67 | Female | 6.47 | 4 | NC* |
| Total | 19.48 | 16 | 82 | Total | 13.16 | 12 | 91 |
| <u>Breast</u> | | | | <u>Non-Hodgkin's Ly</u> | mphoma | | |
| Male | 2.25 | 2 | NC* | Male | 26.87 | 18 | 67 |
| Female | 216.54 | 224 | 103 | Female | 26.56 | 12 | 45 ~- |
| Total | 218.79 | 226 | 103 | Total | 53.44 | 30 | 56 ^- |
| Cervix Uteri | | | | Oral Cavity and Ph | <u>iarynx</u> | | |
| | | | | Male | 21.08 | 17 | 81 |
| Female | 11.98 | 11 | 92 | Female | 11.05 | 3 | NC* |
| | | | | Total | 32.13 | 20 | 62 #- |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 91.00 | 94 | 103 | | | | |
| Female | 96.11 | 71 | 74 ~- | Female | 25.11 | 26 | 104 |
| Total | 187.11 | 165 | 88 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 12.43 | 6 | 48 | Male | 13.90 | 17 | 122 |
| Female | 4.98 | 2 | NC* | Female | 16.59 | 14 | 84 |
| Total | 17.41 | 8 | 46 #- | Total | 30.49 | 31 | 102 |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 4.74 | 5 | 105 | Male | 211.31 | 151 | 71 ^- |
| Female | 4.00 | 1 | NC* | | | | |
| Total | 8.74 | 6 | 69 | | | | |
| Kidney and Renal F | <u>Pelvis</u> | | | <u>Stomach</u> | | | |
| Male | 19.61 | 10 | 51 #- | Male | 15.17 | 8 | 53 |
| Female | 13.28 | 9 | 68 | Female | 10.34 | 6 | 58 |

| Total | 32.89 | 19 | 58 #- | Total | 25.51 | 14 | 55 #- |
|---------------------|-----------------|-----|-------|-------------------|-------------|------|-------|
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 11.15 | 7 | 63 | Male | 6.94 | 2 | NC* |
| Female | 3.18 | 3 | NC* | | | | |
| Total | 14.33 | 10 | 70 | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 14.87 | 11 | 74 | Male | 3.87 | 3 | NC* |
| Female | 12.39 | 8 | 65 | Female | 10.50 | 7 | 67 |
| Total | 27.26 | 19 | 70 | Total | 14.37 | 10 | 70 |
| Liver and Intrahepa | atic Bile Ducts | | | Uteri, Corpus and | Uterus, NOS | | |
| Male | 7.26 | 1 | NC* | | | | |
| Female | 3.44 | 4 | NC* | Female | 41.77 | 36 | 86 |
| Total | 10.70 | 5 | 47 | | | | |
| Lung and Bronchu | <u>s</u> | | | All Sites / Types | | | |
| Male | 112.30 | 74 | 66 ^- | Male | 697.28 | 520 | 75 ^- |
| Female | 92.87 | 74 | 80 | Female | 701.30 | 587 | 84 ^- |
| Total | 205.17 | 148 | 72 ^- | Total | 1398.58 | 1107 | 79 ^- |

Obs = observed case count

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- \sim indicates statistical significance at the p<0.01 level, as well as at the p<0.05 level

Plainfield
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Exp</u> | <u>Obs</u> | SIR |
|--------------------|-------------------|--------------|------------|-------------------------|---------------|------------|-----|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 0.47 | 1 | NC* | Male | 0.27 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.16 | 0 | NC* |
| Total | 0.59 | 1 | NC* | Total | 0.43 | 0 | NC* |
| Brain and Other Co | entral Nervous Sy | <u>rstem</u> | | <u>Multiple Myeloma</u> | | | |
| Male | 0.13 | 0 | NC* | Male | 0.09 | 0 | NC* |
| Female | 0.09 | 0 | NC* | Female | 0.06 | 0 | NC* |
| Total | 0.22 | 0 | NC* | Total | 0.14 | 0 | NC* |
| <u>Breast</u> | | | | Non-Hodgkin's Lyn | <u>nphoma</u> | | |
| Male | 0.03 | 0 | NC* | Male | 0.34 | 0 | NC* |
| Female | 2.13 | 3 | NC* | Female | 0.23 | 0 | NC* |
| Total | 2.16 | 3 | NC* | Total | 0.57 | 0 | NC* |
| Cervix Uteri | | | | Oral Cavity and Pha | <u>ırynx</u> | | |
| | | | | Male | 0.28 | 0 | NC* |
| Female | 0.13 | 0 | NC* | Female | 0.10 | 0 | NC* |
| | | | | Total | 0.38 | 0 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 1.17 | 0 | NC* | | | | |
| Female | 0.72 | 0 | NC* | Female | 0.25 | 0 | NC* |
| Total | 1.89 | 0 | NC* | | | | |

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

[^] indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

| Esophagus | | | | <u>Pancreas</u> | | | |
|----------------------|----------------|---|-----|-------------------|--------------------|---|-------|
| Male | 0.16 | 0 | NC* | Male | 0.18 | 0 | NC* |
| Female | 0.04 | 0 | NC* | Female | 0.13 | 0 | NC* |
| Total | 0.20 | 0 | NC* | Total | 0.31 | 0 | NC* |
| Hodgkin's Disease | | | | Prostate | | | |
| Male | 0.05 | 0 | NC* | Male | 2.74 | 1 | NC* |
| Female | 0.04 | 0 | NC* | | | | |
| Total | 0.09 | 0 | NC* | | | | |
| Kidney and Renal Po | <u>elvis</u> | | | <u>Stomach</u> | | | |
| Male | 0.26 | 0 | NC* | Male | 0.20 | 0 | NC* |
| Female | 0.12 | 0 | NC* | Female | 0.08 | 0 | NC* |
| Total | 0.38 | 0 | NC* | Total | 0.27 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 0.15 | 0 | NC* | Male | 0.07 | 0 | NC* |
| Female | 0.03 | 0 | NC* | | | | |
| Total | 0.18 | 0 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 0.19 | 0 | NC* | Male | 0.05 | 0 | NC* |
| Female | 0.11 | 0 | NC* | Female | 0.11 | 0 | NC* |
| Total | 0.30 | 0 | NC* | Total | 0.16 | 0 | NC* |
| Liver and Intrahepat | tic Bile Ducts | | | Uteri, Corpus and | <u>Uterus, NOS</u> | | |
| Male | 0.09 | 0 | NC* | | | | |
| Female | 0.03 | 0 | NC* | Female | 0.42 | 0 | NC* |
| Total | 0.12 | 0 | NC* | | | | |
| Lung and Bronchus | <u>i</u> | | | All Sites / Types | | | |
| Male | 1.46 | 1 | NC* | Male | 8.98 | 3 | NC* |
| Female | 0.84 | 0 | NC* | Female | 6.34 | 3 | NC* |
| Total | 2.30 | 1 | NC* | Total | 15.33 | 6 | 39 #- |

Obs = observed case count

SIR = standardized incidence ratio [Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the p≤0.05 level
- \sim indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

Plainville
Expected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | SIR | | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> |
|--|------------|------------------------|-----|------------------|------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 4.22 | 7 | 166 | Male | 2.84 | 4 | NC* |
| Female | 1.79 | 2 | NC* | Female | 2.31 | 3 | NC* |
| Total | 6.01 | 9 | 150 | Total | 5.15 | 7 | 136 |
| Brain and Other Central Nervous System | | | | Multiple Myeloma | | | |
| Male | 1.51 | 4 | NC* | Male | 0.81 | 0 | NC* |
| Female | 1.21 | 2 | NC* | Female | 0.79 | 1 | NC* |
| Total | 2.72 | 6 | 220 | Total | 1.60 | 1 | NC* |
| Breast | | Non-Hodakin's Lymphoma | | | | | |

<u>Breast</u> <u>Non-Hodgkin's Lymphoma</u>

| NA-1- | 0.00 | 1 | NO* | N A = I = | 2.50 | 4 | NO* |
|---------------------|-------------------|----|-----|--------------------|--------|-----|-----|
| Male | 0.28 | 1 | NC* | Male | 3.58 | 4 | NC* |
| Female | 29.02 | 21 | 72 | Female | 3.32 | 3 | NC* |
| Total | 29.30 | 22 | 75 | Total | 6.90 | 7 | 101 |
| <u>Cervix Uteri</u> | | | | Oral Cavity and Pl | | | |
| | | | | Male | 2.92 | 0 | NC* |
| Female | 1.81 | 2 | NC* | Female | 1.42 | 2 | NC* |
| | | | | Total | 4.34 | 2 | NC* |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 10.64 | 10 | 94 | | | | |
| Female | 11.19 | 9 | 80 | Female | 3.42 | 1 | NC* |
| Total | 21.83 | 19 | 87 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 1.59 | 3 | NC* | Male | 1.70 | 0 | NC* |
| Female | 0.58 | 0 | NC* | Female | 1.95 | 1 | NC* |
| Total | 2.16 | 3 | NC* | Total | 3.65 | 1 | NC* |
| Hodgkin's Disease | | | | <u>Prostate</u> | | | |
| Male | 0.78 | 1 | NC* | Male | 25.84 | 16 | 62 |
| Female | 0.61 | 2 | NC* | | | | |
| Total | 1.39 | 3 | NC* | | | | |
| Kidney and Renal P | <u>Pelvis</u> | | | <u>Stomach</u> | | | |
| Male | 2.58 | 1 | NC* | Male | 1.81 | 0 | NC* |
| Female | 1.68 | 0 | NC* | Female | 1.21 | 0 | NC* |
| Total | 4.26 | 1 | NC* | Total | 3.02 | 0 | NC* |
| <u>Larynx</u> | | | | <u>Testis</u> | | | |
| Male | 1.48 | 1 | NC* | Male | 1.23 | 1 | NC* |
| Female | 0.42 | 0 | NC* | | | | |
| Total | 1.90 | 1 | NC* | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | |
| Male | 1.93 | 0 | NC* | Male | 0.62 | 1 | NC* |
| Female | 1.59 | 3 | NC* | Female | 1.63 | 3 | NC* |
| Total | 3.53 | 3 | NC* | Total | 2.25 | 4 | NC* |
| Liver and Intrahepa | | | | Uteri, Corpus and | | | |
| Male | 0.95 | 2 | NC* | <u>, p</u> | | | |
| Female | 0.41 | 0 | NC* | Female | 5.53 | 3 | NC* |
| Total | 1.36 | 2 | NC* | | | - | |
| Lung and Bronchus | | - | 110 | All Sites / Types | | | |
| Male | <u>s</u> 13.72 | 21 | 153 | Male | 87.04 | 80 | 92 |
| Female | 11.59 | 10 | 86 | Female | 90.00 | 77 | 86 |
| Total | 25.31 | 31 | 122 | Total | 177.04 | 157 | 89 |
| i Ulai | ۷۵.۵۱ | JΙ | ١٧٧ | าบเลา | 177.04 | 107 | 07 |

Obs = observed case count

SIR = standardized incidence ratio [Obs / Exp) X 100]

Plymouth

^{*} = SIR and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the p<0.05 level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

| | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> | | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> |
|-----------------------------|-----------------|--------------|------------|------------------------|---------------|------------|------------|
| Bladder, Urinary | | | | Melanoma of Skin | <u>l</u> | | |
| Male | 28.22 | 33 | 117 | Male | 18.43 | 26 | 141 |
| Female | 10.99 | 15 | 136 | Female | 14.28 | 11 | 77 |
| Total | 39.21 | 48 | 122 | Total | 32.71 | 37 | 113 |
| Brain and Other Ce | ntral Nervous S | <u>ystem</u> | | Multiple Myeloma | | | |
| Male | 9.74 | 11 | 113 | Male | 5.37 | 8 | 149 |
| Female | 7.59 | 9 | 119 | Female | 4.88 | 5 | 103 |
| Total | 17.33 | 20 | 115 | Total | 10.24 | 13 | 127 |
| <u>Breast</u> | | | | Non-Hodgkin's Ly | <u>mphoma</u> | | |
| Male | 1.83 | 2 | NC* | Male | 23.28 | 17 | 73 |
| Female | 178.69 | 168 | 94 | Female | 20.41 | 25 | 122 |
| Total | 180.52 | 170 | 94 | Total | 43.69 | 42 | 96 |
| Cervix Uteri | | | | Oral Cavity and Ph | <u>narynx</u> | | |
| | | | | Male | 18.98 | 25 | 132 |
| Female | 11.13 | 12 | 108 | Female | 8.75 | 14 | 160 |
| | | | | Total | 27.72 | 39 | 141 #+ |
| Colon / Rectum | | | | <u>Ovary</u> | | | |
| Male | 70.51 | 80 | 113 | | | | |
| Female | 69.08 | 54 | 78 | Female | 21.10 | 13 | 62 |
| Total | 139.58 | 134 | 96 | | | | |
| <u>Esophagus</u> | | | | <u>Pancreas</u> | | | |
| Male | 10.39 | 7 | 67 | Male | 11.22 | 9 | 80 |
| Female | 3.53 | 2 | NC* | Female | 11.85 | 11 | 93 |
| Total | 13.91 | 9 | 65 | Total | 23.07 | 20 | 87 |
| Hodgkin's Disease | | • | 00 | <u>Prostate</u> | 20.07 | | 0, |
| Male | 4.81 | 7 | 146 | Male | 167.57 | 152 | 91 |
| Female | 3.82 | 3 | NC* | Widio | 107.07 | 102 | 71 |
| Total | 8.63 | 10 | 116 | | | | |
| Kidney and Renal Pelvis | | | Stomach | | | | |
| Male Male | 16.86 | 21 | 125 | <u>Stomach</u> Male | 12.06 | 9 | 75 |
| Female | 10.27 | 18 | 175 #+ | Female | 7.51 | 2 | NC* |
| Total | 27.13 | 39 | 144 #+ | Total | 19.57 | 11 | 56 |
| <u>Larynx</u> | 27.13 | 37 | 144 ## | <u>Testis</u> | 17.57 | 11 | 30 |
| Male | 9.64 | 9 | 93 | Male | 7.30 | 10 | 137 |
| Female | 2.53 | 3 | NC* | Widic | 7.50 | 10 | 137 |
| Total | 12.17 | 12 | 99 | | | | |
| <u>Leukemia</u> | 12.17 | 12 | 77 | <u>Thyroid</u> | | | |
| Male | 12.83 | 15 | 117 | <u>myroid</u> Male | 3.84 | 2 | NC* |
| Female | 12.03 | 10 | 99 | Female | 3.04 10.11 | 10 | 99 |
| Total | 22.98 | 25 | 109 | Total | 13.95 | 10 | |
| | | 20 | 109 | | | 12 | 86 |
| Liver and Intrahepa Male | 6.17 | 5 | 81 | Uteri, Corpus and | oterus, NOS | | |
| | | | | Famala | 22.02 | 21 | 01 |
| Female | 2.52 | 0 | NC* | Female | 33.93 | 31 | 91 |
| Total | 8.69 | 5 | 58 | All Chas / T | | | |
| Lung and Bronchu | | 100 | 110 | All Sites / Types | F/0.04 | F07 | 100 |
| Male | 89.56 | 100 | 112 | Male | 568.24 | 587 | 103 |
| Female | 69.96 | 76 | 109 | Female | 553.76 | 532 | 96 |
| Total | 159.51 | 176 | 110 | Total | 1122.00 | 1119 | 100 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $p \le 0.05$ level
- \sim indicates statistical significance at the p<0.01 level, as well as at the p<0.05 level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels

PlymptonExpected and Observed Case Counts, with Standardized Incidence Ratios, 1994 - 1998

| | <u>Exp</u> | <u>Obs</u> | <u>SIR</u> | | <u>Ехр</u> | <u>Obs</u> | <u>SIR</u> | |
|---------------------|-----------------------|--------------|-----------------|-------------------------|---------------|------------|------------|--|
| Bladder, Urinary | | | | Melanoma of Skin | | | | |
| Male | 1.20 | 3 | NC* | Male | 0.93 | 1 | NC* | |
| Female | 0.44 | 0 | NC* | Female | 0.70 | 0 | NC* | |
| Total | 1.63 | 3 | NC* | Total | 1.64 | 1 | NC* | |
| Brain and Other Cen | <u>tral Nervous S</u> | <u>ystem</u> | | Multiple Myeloma | | | | |
| Male | 0.51 | 0 | NC* | Male | 0.25 | 0 | NC* | |
| Female | 0.37 | 1 | NC* | Female | 0.22 | 1 | NC* | |
| Total | 0.88 | 1 | NC* | Total | 0.47 | 1 | NC* | |
| <u>Breast</u> | | | | Non-Hodgkin's Lyr | <u>mphoma</u> | | | |
| Male | 0.08 | 0 | NC* | Male | 1.13 | 0 | NC* | |
| Female | 9.00 | 6 | 67 | Female | 0.91 | 2 | NC* | |
| Total | 9.08 | 6 | 66 | Total | 2.04 | 2 | NC* | |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | | |
| | | | | Male | 1.02 | 0 | NC* | |
| Female | 0.58 | 0 | NC* | Female | 0.41 | 0 | NC* | |
| | | | | Total | 1.44 | 0 | NC* | |
| Colon / Rectum | | | | <u>Ovary</u> | | | | |
| Male | 3.05 | 6 | 197 | | | | | |
| Female | 2.71 | 2 | NC* | Female | 1.07 | 1 | NC* | |
| Total | 5.76 | 8 | 139 | | | | | |
| Esophagus | | | | <u>Pancreas</u> | | | | |
| Male | 0.52 | 0 | NC* | Male | 0.52 | 0 | NC* | |
| Female | 0.14 | 0 | NC* | Female | 0.48 | 0 | NC* | |
| Total | 0.66 | 0 | NC* | Total | 1.00 | 0 | NC* | |
| Hodgkin's Disease | | | <u>Prostate</u> | | | | | |
| Male | 0.25 | 0 | NC* | Male | 8.07 | 5 | 62 | |
| Female | 0.19 | 0 | NC* | | | | | |
| Total | 0.44 | 0 | NC* | | | | | |
| Kidney and Renal Pe | <u>elvis</u> | | | Stomach | | | | |
| Male | 0.86 | 2 | NC* | Male | 0.53 | 0 | NC* | |
| Female | 0.49 | 0 | NC* | Female | 0.29 | 0 | NC* | |
| Total | 1.35 | 2 | NC* | Total | 0.82 | 0 | NC* | |
| <u>Larynx</u> | | | | <u>Testis</u> | | | | |
| Male | 0.51 | 0 | NC* | Male | 0.38 | 0 | NC* | |
| Female | 0.13 | 0 | NC* | | | | | |
| Total | 0.64 | 0 | NC* | | | | | |
| <u>Leukemia</u> | | | | <u>Thyroid</u> | | | | |
| Male | 0.61 | 1 | NC* | Male | 0.21 | 0 | NC* | |
| Female | 0.46 | 0 | NC* | Female | 0.52 | 0 | NC* | |
| | | | | | | | | |

| Total | 1.07 | 1 | NC* | Total | 0.74 | 0 | NC* |
|-----------------------------------|------|---|-----|-------------------------------|-------|----|-----|
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 0.31 | 0 | NC* | | | | |
| Female | 0.11 | 0 | NC* | Female | 1.74 | 0 | NC* |
| Total | 0.42 | 0 | NC* | | | | |
| <u>Lung and Bronchus</u> | | | | All Sites / Types | | | |
| Male | 4.24 | 2 | NC* | Male | 26.99 | 24 | 89 |
| Female | 3.32 | 1 | NC* | Female | 25.98 | 16 | 62 |
| Total | 7.56 | 3 | NC* | Total | 52.97 | 40 | 76 |

Obs = observed case count

- * = **SIR** and statistical significance not calculated when **Obs** < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the p≤0.05 level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level
- ^ indicates statistical significance at the $p \le 0.001$ level, as well as at the $p \le 0.01$ and $p \le 0.05$ levels